|
|
Post by sweedee79 on Feb 25, 2022 9:53:19 GMT -5
I'm out!!! It's been over a decade of this.. and it doesn't seem to get better.... All that I saw in both calls was someone trying to calm the storm...I'm off to find something better..
|
|
|
|
Post by sayhey24 on Feb 25, 2022 10:04:16 GMT -5
It was extremely bad news and we know the FDA cannot be trusted to be fair or quick and I feel a little bad that Martine is being treated so badly by them. I am not a trusting person even if you think I am because of my support for Dr. Castagna’s leadership as CEO. I honestly feel he’s done a good job and I am grateful for his efforts and his conservative nature when it comes to spending Mannkind’s money. I appreciate that he’s cautious enough to let things get settled before counting on the revenue. That is being fiscally responsible. But where my distrust is maybe too strong is with regard to how Afrezza and now perhaps Tyvaso DPI has been treated by the FDA. The 3rd CRL, the AdComm, the black box label, all of it has been horrible to Mannkind and the PWDs that have benefitted from Afrezza. I don’t know what will happen to Tyvaso DPI, but my confidence is very low that the end result from the FDA will simply be, “OK, we looked, you’re cool, carry on”. I am curious what Nate Pile’s advice is. For myself, I unwound a portion of my position and reinvested elsewhere. GLTALs. How about the 2nd CRL about cleaning the medtone inhaler and reading the printing on the foil package? To be honest, today I am on the other side of your trade. Will the FDA approve Tyvaso DPI, I think so. FDKP is highly safe and has years of clinical data to back it up. I think this was a case of the FDA having to dot the i's and cross the t's to complete due diligence - just in case. I also think they were overwhelmed with the response. I also think they may have questions on the data provided which will happen by May. When I look at MNKD and their pipeline, they have a number of serious products in the works. At the same time Mike is now saying afrezza will be break-even in 2023. BP must be losing their minds today. MNKD by now was suppose to be bankrupt and afrezza was suppose to be buried 100ft deep. Instead they are sitting on a pile of cash and talking about afrezza becoming a profitable product. One thing about Mike is he is learning from his past mistakes and willing to pivot. I really like the "seeing is believing" campaign. Who knows maybe we will have some live demos during the 82nd ADA session demonstrating "seeing is believing". I have to give Bill from VDex some credit with his persistence and whitepapers in changing some of Mike's thinking. Today, I think we are in a much better place and the future looks very bright. |
|
|
|
Post by Clement on Feb 25, 2022 10:14:43 GMT -5
I'm out!!! It's been over a decade of this.. and it doesn't seem to get better.... All that I saw in both calls was someone trying to calm the storm...I'm off to find something better.. |
|
|
|
Post by brentie on Feb 25, 2022 10:16:36 GMT -5
I'm out!!! It's been over a decade of this.. and it doesn't seem to get better.... All that I saw in both calls was someone trying to calm the storm...I'm off to find something better.. Well nobody can say that you didn't give it a fair shake. I hope your next stock makes up for all the aggravation! Keep in touch, sweedee. |
|
|
|
Post by liane on Feb 25, 2022 10:35:20 GMT -5
How about the 2nd CRL about cleaning the medtone inhaler and reading the printing on the foil package? To be honest, today I am on the other side of your trade. Will the FDA approve Tyvaso DPI, I think so. FDKP is highly safe and has years of clinical data to back it up. I think this was a case of the FDA having to dot the i's and cross the t's to complete due diligence - just in case. I also think they were overwhelmed with the response. I also think they may have questions on the data provided which will happen by May. When I look at MNKD and their pipeline, they have a number of serious products in the works. At the same time Mike is now saying afrezza will be break-even in 2023. BP must be losing their minds today. MNKD by now was suppose to be bankrupt and afrezza was suppose to be buried 100ft deep. Instead they are sitting on a pile of cash and talking about afrezza becoming a profitable product. One thing about Mike is he is learning from his past mistakes and willing to pivot. I really like the "seeing is believing" campaign. Who knows maybe we will have some live demos during the 82nd ADA session demonstrating "seeing is believing". I have to give Bill from VDex some credit with his persistence and whitepapers in changing some of Mike's thinking. Today, I think we are in a much better place and the future looks very bright. I do believe this is true. Hopefully it will serve us well in the long term |
|
|
|
Post by sweedee79 on Feb 25, 2022 10:36:08 GMT -5
♥️♥️Love you guys.. you are like family!!! I'll be around!!!
|
|
|
|
Post by akemp3000 on Feb 25, 2022 10:47:11 GMT -5
♥️♥️Love you guys.. you are like family!!! I'll be around!!! There's a line from a movie that comes to mind... "It's been a pleasure doing battle with you!" |
|
|
|
Post by lennymnkd on Feb 25, 2022 10:51:29 GMT -5
♥️♥️Love you guys.. you are like family!!! I'll be around!!! Sweedee , it’s not that easy 😀 |
|
|
|
Post by harryx1 on Feb 25, 2022 11:32:44 GMT -5
It was extremely bad news and we know the FDA cannot be trusted to be fair or quick and I feel a little bad that Martine is being treated so badly by them. I am not a trusting person even if you think I am because of my support for Dr. Castagna’s leadership as CEO. I honestly feel he’s done a good job and I am grateful for his efforts and his conservative nature when it comes to spending Mannkind’s money. I appreciate that he’s cautious enough to let things get settled before counting on the revenue. That is being fiscally responsible. But where my distrust is maybe too strong is with regard to how Afrezza and now perhaps Tyvaso DPI has been treated by the FDA. The 3rd CRL, the AdComm, the black box label, all of it has been horrible to Mannkind and the PWDs that have benefitted from Afrezza. I don’t know what will happen to Tyvaso DPI, but my confidence is very low that the end result from the FDA will simply be, “OK, we looked, you’re cool, carry on”. I am curious what Nate Pile’s advice is. For myself, I unwound a portion of my position and reinvested elsewhere. GLTALs. How about the 2nd CRL about cleaning the medtone inhaler and reading the printing on the foil package? To be honest, today I am on the other side of your trade. Will the FDA approve Tyvaso DPI, I think so. FDKP is highly safe and has years of clinical data to back it up. I think this was a case of the FDA having to dot the i's and cross the t's to complete due diligence - just in case. I also think they were overwhelmed with the response. I also think they may have questions on the data provided which will happen by May. When I look at MNKD and their pipeline, they have a number of serious products in the works. At the same time Mike is now saying afrezza will be break-even in 2023. BP must be losing their minds today. MNKD by now was suppose to be bankrupt and afrezza was suppose to be buried 100ft deep. Instead they are sitting on a pile of cash and talking about afrezza becoming a profitable product. One thing about Mike is he is learning from his past mistakes and willing to pivot. I really like the "seeing is believing" campaign. Who knows maybe we will have some live demos during the 82nd ADA session demonstrating "seeing is believing". I have to give Bill from VDex some credit with his persistence and whitepapers in changing some of Mike's thinking. Today, I think we are in a much better place and the future looks very bright. Yet the FDA didn't have a single question about LQDA's excipient and are 100% fine with 2 weeks of safety testing!?!?!??!?!? The whole situation reeks to me, the FDA received the citizens petition Jul 8th 2021, issued the CRL Oct 15th 2021 and stated it had not looked at the CP yet. WTF!?!?!?!? Then sent a letter Jan 4th 2022 to the ambulance chasing lawyer stating that they have not yet resolved the issues he raised in the CP. All the while telling UTHR that they would have a decision in Feb. IMO it was a planned stall tactic by the person in charge of the Tyvaso DPI case to delay as long as possible since they are either being paid off, blackmailed or related to someone at LQDA or a hedge fund. JMHO. |
|
|
|
Post by peppy on Feb 25, 2022 11:51:29 GMT -5
The whole, bringing a new drug to market has been a learning experience as well as a lesson in corruption. We can see with our eye balls the superior blood glucose control facilitated by 12 mins to onset of action, 30 min peak action and 90 mins out of the system, with add on doses as needed.  Versus peak onset of action at 2 hours and 5 hours for clearance.  The corruption, the non inferior label allows for insurance companies to say they offer another brand. additionally 45% of the US population have employer covered health insurance. 20% medicare, the other 35% the hoop? Prior to CGM's the physicians could ignore this. Now it is ignored with a hemoglobin A1c. |
|
|
|
Post by sweedee79 on Feb 25, 2022 12:07:42 GMT -5
How about the 2nd CRL about cleaning the medtone inhaler and reading the printing on the foil package? To be honest, today I am on the other side of your trade. Will the FDA approve Tyvaso DPI, I think so. FDKP is highly safe and has years of clinical data to back it up. I think this was a case of the FDA having to dot the i's and cross the t's to complete due diligence - just in case. I also think they were overwhelmed with the response. I also think they may have questions on the data provided which will happen by May. When I look at MNKD and their pipeline, they have a number of serious products in the works. At the same time Mike is now saying afrezza will be break-even in 2023. BP must be losing their minds today. MNKD by now was suppose to be bankrupt and afrezza was suppose to be buried 100ft deep. Instead they are sitting on a pile of cash and talking about afrezza becoming a profitable product. One thing about Mike is he is learning from his past mistakes and willing to pivot. I really like the "seeing is believing" campaign. Who knows maybe we will have some live demos during the 82nd ADA session demonstrating "seeing is believing". I have to give Bill from VDex some credit with his persistence and whitepapers in changing some of Mike's thinking. Today, I think we are in a much better place and the future looks very bright. Yet the FDA didn't have a single question about LQDA's excipient and are 100% fine with 2 weeks of safety testing!?!?!??!?!? The whole situation reeks to me, the FDA received the citizens petition Jul 8th 2021, issued the CRL Oct 15th 2021 and stated it had not looked at the CP yet. WTF!?!?!?!? Then sent a letter Jan 4th 2022 to the ambulance chasing lawyer stating that they have not yet resolved the issues he raised in the CP. All the while telling UTHR that they would have a decision in Feb. IMO it was a planned stall tactic by the person in charge of the Tyvaso DPI case to delay as long as possible since they are either being paid off, blackmailed or related to someone at LQDA or a hedge fund. JMHO. IMO you could not be more RIGHT!!!! Something really shitty has happened!! I can't put my finger on it... Or say exactly what... I JUST KNOW IT!! |
|
|
|
Post by radgray68 on Feb 25, 2022 12:20:36 GMT -5
I hear ya Swedee. I don't have to look. It's the thumping sensation in our rear ends that gives it away.
|
|
|
|
Post by prcgorman2 on Feb 25, 2022 14:18:41 GMT -5
It was extremely bad news and we know the FDA cannot be trusted to be fair or quick and I feel a little bad that Martine is being treated so badly by them. I am not a trusting person even if you think I am because of my support for Dr. Castagna’s leadership as CEO. I honestly feel he’s done a good job and I am grateful for his efforts and his conservative nature when it comes to spending Mannkind’s money. I appreciate that he’s cautious enough to let things get settled before counting on the revenue. That is being fiscally responsible. But where my distrust is maybe too strong is with regard to how Afrezza and now perhaps Tyvaso DPI has been treated by the FDA. The 3rd CRL, the AdComm, the black box label, all of it has been horrible to Mannkind and the PWDs that have benefitted from Afrezza. I don’t know what will happen to Tyvaso DPI, but my confidence is very low that the end result from the FDA will simply be, “OK, we looked, you’re cool, carry on”. I am curious what Nate Pile’s advice is. For myself, I unwound a portion of my position and reinvested elsewhere. GLTALs. How about the 2nd CRL about cleaning the medtone inhaler and reading the printing on the foil package? To be honest, today I am on the other side of your trade. Will the FDA approve Tyvaso DPI, I think so. FDKP is highly safe and has years of clinical data to back it up. I think this was a case of the FDA having to dot the i's and cross the t's to complete due diligence - just in case. I also think they were overwhelmed with the response. I also think they may have questions on the data provided which will happen by May. When I look at MNKD and their pipeline, they have a number of serious products in the works. At the same time Mike is now saying afrezza will be break-even in 2023. BP must be losing their minds today. MNKD by now was suppose to be bankrupt and afrezza was suppose to be buried 100ft deep. Instead they are sitting on a pile of cash and talking about afrezza becoming a profitable product. One thing about Mike is he is learning from his past mistakes and willing to pivot. I really like the "seeing is believing" campaign. Who knows maybe we will have some live demos during the 82nd ADA session demonstrating "seeing is believing". I have to give Bill from VDex some credit with his persistence and whitepapers in changing some of Mike's thinking. Today, I think we are in a much better place and the future looks very bright. You expressed my hope better than I could have, but my confidence is very low. I do not expect to reinvest in MNKD at the level I once held, but I am taking a wait and see. I guess I could change my sentiment to long waiting on the sidelines. This is a hard pill to swallow. |
|
|
|
Post by MnkdWASmyRtrmntPlan on Feb 25, 2022 14:29:36 GMT -5
There is too much good news going on. 2 years from now this stock will be, well, very much higher than it is right now. This price is a screaming steal. I just hope it holds for awhile while I work on getting more cash available to buy some more. It will probably take me til next Thursday to get it tranferred.
|
|
|
|
Post by harryx1 on Feb 25, 2022 14:32:25 GMT -5
I'm on a rampage today...
|
|
